$CBIO SEC Filings

Filed On	Filing
15 Oct 2026	8-K: Other Events On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plu...
18 Sep 2026	Form 4: Lynch Ryan, See Remarks Sold 240 shares ($4.3K)
18 Sep 2026	Form 4: Pinkas Jan, Chief Scientific Officer Sold 658 shares ($11.8K)
18 Sep 2026	Form 4: Im Ellie Eunkyung, Chief Medical Officer Sold 623 shares ($11.2K)
18 Sep 2026	Form 4: Scalzo Richard William, Chief Financial Officer Sold 568 shares ($10.2K)
18 Sep 2026	Form 4: Bispham Barbara Harlin, See Remarks Sold 620 shares ($11.1K)
18 Sep 2026	Form 4: Brumm Joshua T, Director Sold 1,610 shares ($28.8K) · Sold 7,837 shares ($131K)
18 Sep 2026	Form 4: McNeill Jonathan, President and COO Sold 731 shares ($13.1K) · Sold 3,839 shares ($64.1K)
18 Sep 2026	S-8
17 Sep 2026	144
17 Sep 2026	144
16 Sep 2026	144
16 Sep 2026	144
14 Aug 2026	SCHEDULE 13G/A
31 Jul 2026	EFFECT
30 Jul 2026	POS AM
30 Jul 2026	424B3
30 Jul 2026	10-Q
30 Jul 2026	8-K: Results of Operations and Financial Condition
20 Jul 2026	SCHEDULE 13D/A

Comments